Associated Papers
Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen.
Abdelfattah EK et al.
Pharmaceuticals (basel, Switzerland), 2025
Indicators of HSV1 Infection, ECM-Receptor Interaction, and Chromatin Modulation in a Nuclear Family with Schizophrenia.
Huang YC et al.
Journal of Personalized Medicine, 2023
Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy.
Bagdasaryan AA et al.
Cancers, 2022
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.
Muñiz P et al.
Frontiers in Immunology, 2022
Common ALDH3A1 Gene Variant Associated with Keratoconus Risk in the Polish Population.
Berdyński M et al.
Journal of Clinical Medicine, 2021
Association with Corneal Remodeling Related Genes, ALDH3A1, LOX, and SPARC Genes Variations in Korean Keratoconus Patients.
Mok JW et al.
Korean Journal of Ophthalmology : Kjo, 2021
A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases.
Jian M et al.
Journal of Translational Medicine, 2020
Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a CYP2B6*7 variant.
Ming Z et al.
Pharmacogenomics, 2019
Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population.
Afsar NA et al.
Scientific Reports, 2019
Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
Tecza K et al.
Oncotarget, 2018
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Vulsteke C et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2013
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
Afsar NA et al.
European Journal of Clinical Pharmacology, 2012
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Ekhart C et al.
Pharmacogenetics and Genomics, 2008
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C et al.
Pharmacogenetics and Genomics, 2008
Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease.
Vasiliou V et al.
Pharmacology, 2000